These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 22284689

  • 1. Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs.
    Walker GV, Niikura N, Yang W, Rohren E, Valero V, Woodward WA, Alvarez RH, Lucci A, Ueno NT, Buchholz TA.
    Int J Radiat Oncol Biol Phys; 2012 Aug 01; 83(5):1381-6. PubMed ID: 22284689
    [Abstract] [Full Text] [Related]

  • 2. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures.
    Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G, Fontanillas M, Pons F.
    J Clin Oncol; 2008 Oct 10; 26(29):4746-51. PubMed ID: 18695254
    [Abstract] [Full Text] [Related]

  • 3. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
    Ng SP, David S, Alamgeer M, Ganju V.
    Int J Radiat Oncol Biol Phys; 2015 Sep 01; 93(1):111-7. PubMed ID: 26279029
    [Abstract] [Full Text] [Related]

  • 4. [18F]FDG PET/CT in the staging of inflammatory breast cancer: A systematic review.
    van Uden DJP, Prins MW, Siesling S, de Wilt JHW, Blanken-Peeters CFJM, Aarntzen EHJG.
    Crit Rev Oncol Hematol; 2020 Jul 01; 151():102943. PubMed ID: 32416347
    [Abstract] [Full Text] [Related]

  • 5. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data.
    Carkaci S, Macapinlac HA, Cristofanilli M, Mawlawi O, Rohren E, Gonzalez Angulo AM, Dawood S, Resetkova E, Le-Petross HT, Yang WT.
    J Nucl Med; 2009 Feb 01; 50(2):231-8. PubMed ID: 19164229
    [Abstract] [Full Text] [Related]

  • 6. Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning.
    Jacene HA, DiPiro PJ, Bellon J, Hu J, Cheng SC, Warren L, Schlosnagle E, Nakhlis F, Rosenbluth JM, Yeh E, Overmoyer B.
    Breast Cancer Res Treat; 2020 Jun 01; 181(2):383-390. PubMed ID: 32318957
    [Abstract] [Full Text] [Related]

  • 7. Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer.
    Niikura N, Liu J, Costelloe CM, Palla SL, Madewell JE, Hayashi N, Yu TK, Tokuda Y, Theriault RL, Hortobagyi GN, Ueno NT.
    Oncologist; 2011 Jun 01; 16(6):772-82. PubMed ID: 21632453
    [Abstract] [Full Text] [Related]

  • 8. 18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging.
    Groheux D, Giacchetti S, Delord M, Hindié E, Vercellino L, Cuvier C, Toubert ME, Merlet P, Hennequin C, Espié M.
    J Nucl Med; 2013 Jan 01; 54(1):5-11. PubMed ID: 23213197
    [Abstract] [Full Text] [Related]

  • 9. Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade.
    Jacene HA, Youn T, DiPiro PJ, Hu J, Cheng SC, Franchetti Y, Shah H, Bellon JR, Warren L, Schlosnagle E, Nakhlis F, Rosenbluth J, Yeh E, Overmoyer B, Dana-Farber Cancer Institute Inflammatory Breast Cancer Program.
    Clin Breast Cancer; 2019 Apr 01; 19(2):146-155. PubMed ID: 30584057
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of a Case of Inflammatory Breast Cancer with 18F-FDG PET/CT.
    Al-Faham Z, Al-Katib S, Jaiyesimi I, Bhavnagri S.
    J Nucl Med Technol; 2015 Dec 01; 43(4):289-91. PubMed ID: 26584614
    [Abstract] [Full Text] [Related]

  • 11. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
    Zhang X, Wu F, Han P.
    Hell J Nucl Med; 2014 Dec 01; 17(3):177-83. PubMed ID: 25526754
    [Abstract] [Full Text] [Related]

  • 12. Baseline FDG PET-CT imaging is necessary for newly diagnosed inflammatory breast cancer patients: a narrative review.
    Patel MM, Le-Petross HT.
    Chin Clin Oncol; 2021 Dec 01; 10(6):56. PubMed ID: 34806397
    [Abstract] [Full Text] [Related]

  • 13. Contrast-enhanced [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography for staging and radiotherapy planning in patients with anal cancer.
    Bannas P, Weber C, Adam G, Frenzel T, Derlin T, Mester J, Klutmann S.
    Int J Radiat Oncol Biol Phys; 2011 Oct 01; 81(2):445-51. PubMed ID: 20832181
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients.
    Riegger C, Koeninger A, Hartung V, Otterbach F, Kimmig R, Forsting M, Bockisch A, Antoch G, Heusner TA.
    Acta Radiol; 2012 Dec 01; 53(10):1092-8. PubMed ID: 23002144
    [Abstract] [Full Text] [Related]

  • 15. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.
    Alberini JL, Lerebours F, Wartski M, Fourme E, Le Stanc E, Gontier E, Madar O, Cherel P, Pecking AP.
    Cancer; 2009 Nov 01; 115(21):5038-47. PubMed ID: 19645022
    [Abstract] [Full Text] [Related]

  • 16. FDG/PET-CT-Based Lymph Node Atlas in Breast Cancer Patients.
    Borm KJ, Voppichler J, Düsberg M, Oechsner M, Vag T, Weber W, Combs SE, Duma MN.
    Int J Radiat Oncol Biol Phys; 2019 Mar 01; 103(3):574-582. PubMed ID: 30118822
    [Abstract] [Full Text] [Related]

  • 17. Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve disease recurrence prediction in postmastectomy breast cancer patients with 1 to 3 positive axillary lymph nodes.
    Nakajima N, Kataoka M, Sugawara Y, Ochi T, Kiyoto S, Ohsumi S, Mochizuki T.
    Int J Radiat Oncol Biol Phys; 2013 Nov 15; 87(4):738-46. PubMed ID: 24064322
    [Abstract] [Full Text] [Related]

  • 18. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer.
    Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, De Leyn PR, De Wever W, Verbeken EK, Gatti GG, Huyskens DP, Kutcher GJ.
    Radiother Oncol; 2000 Jun 15; 55(3):317-24. PubMed ID: 10869746
    [Abstract] [Full Text] [Related]

  • 19. Detection of isolated ipsilateral regional lymph node recurrences by F18-fluorodeoxyglucose positron emission tomography-CT in follow-up of postoperative breast cancer patients.
    Ohsumi S, Inoue T, Kiyoto S, Hara F, Takahashi M, Takabatake D, Takashima S, Aogi K, Takashima S.
    Breast Cancer Res Treat; 2011 Nov 15; 130(1):267-72. PubMed ID: 21590272
    [Abstract] [Full Text] [Related]

  • 20. The role of (18)F-FDG PET/CT in initial staging of patients with locally advanced breast carcinoma with an emphasis on M staging.
    Mittal BR, Manohar K, Kashyap R, Bhattacharya A, Singh B, Singh G.
    Hell J Nucl Med; 2011 Nov 15; 14(2):135-9. PubMed ID: 21761015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.